Viamet raises $4M for metalloenzyme-targeting drugs

June 7, 2007 | David P. Hamilton
View Comments

Research Triangle Park, N.C.-based Viamet raised $4 million in a first round of funding. The round was co-led by Hatteras Venture Partners and Intersouth Partners.

Viamet is developing drugs that target metalloenzymes — a diverse group of catalyst molecules that include metal atoms — in infectious disease, inflammation and cancer. The company was founded in 2005.

Next Story:
Previous Story:

Print
Email
Twitter
Facebook
Google Buzz
LinkedIn
Digg
StumbleUpon
Reddit
Delicious
Google
More...

Tags: , ,

Photo of David P. Hamilton

About the Author,

David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.

blog comments powered by Disqus